Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characteristics, Treatment Patterns, and Clinical Outcomes in Non-intensive Chemotherapy Acute Myeloid Leukemia (AML) Patients - a US Real-World Study Using Electronic Medical Record Data

Next Previous
Trial Profile

Characteristics, Treatment Patterns, and Clinical Outcomes in Non-intensive Chemotherapy Acute Myeloid Leukemia (AML) Patients - a US Real-World Study Using Electronic Medical Record Data

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Glasdegib (Primary) ; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 22 Dec 2020 Planned End Date changed from 28 Feb 2021 to 31 Mar 2021.
  • 22 Dec 2020 Planned primary completion date changed from 28 Feb 2021 to 31 Mar 2021.
  • 22 Dec 2020 Planned initiation date changed from 30 Jun 2020 to 31 Oct 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top